Fatal Danaparoid-sodium Induced Thrombocytopenia and Arterial Thromboses

Please copy the URL and add it into your RSS Feed Reader.

Thromb Haemost 1998; 80(03): 530
DOI: 10.1055/s-0037-1615249

Letters to the Editor

Schattauer GmbH

Authors

Bernard Tardy

¹From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
Brigitte Tardy-Poncet

¹From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
Alain Viallon

¹From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
Michèle Piot

¹From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
Eliane Mazet

¹From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France

Received 19 March 1998

Accepted after revision 07 May 1998

Publication Date:
08 December 2017 (online)

References
1 Magnani HN. Heparin-induced thrombocytopenia: an overview of 230 patients treated with danaparoid-sodium (Org 10172). Thromb Haemost 1993; 70: 554-61.

Reference Link Ris
Thieme Connect PubMed Search in Google Scholar
2 Tardy-Poncet B. French experience in the use of danaparoid-sodium as an alternative antithrombotic treatment for patients with heparin induced thrombocytopenia. Thromb Haemost 1998 (Suppl) 1825a.

Reference Link Ris
PubMed Search in Google Scholar
3 Warkentin TE. Danaparoid (Danaparoid-sodium) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin significance of in vitro cross-reactivity of danaparoid for HIT-IgG. Blood 1996; 88 (Suppl. 01) 626a.

Reference Link Ris
PubMed Search in Google Scholar